Reviva Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -20,200,014,105 | -4,005 | -6,040 | -6,416 |
EBIT | -8,035 | -12,113 | -12,954 | |
Net Income | -19,864,885,329 | -4,010 | -6,053 | -6,432 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -24,594,624,203 | -5,589 | -5,012 | -8,194 |
Cash | 14,438,792,000 | 13,183 | 10,363 | 5,289 |
Basic Shares | 3,628 | 3,634 | 2,492 | 2,432 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -20,200,031,000 | -29,880 | -39,210 | -24,111 |
EBIT | -60,679 | -78,713 | -24,306 | |
Net Income | -19,864,902,000 | -29,918 | -39,260 | -24,339 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -24,594,643,000 | -33,543 | -28,324 | -18,960 |
Cash | 14,438,792,000 | 13,476 | 23,367 | 18,519 |
Basic Shares | 3,628 | 1,657 | 1,189 | 975 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$0.57 |
2025-12-31 | -$5.19 |
2025-09-30 | -$0.06 |
2025-06-30 | -$0.12 |
